Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
136. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in… read more |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi… read more |
View |
137. |
ECCT/23/03/04 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus… read more |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
View |
138. |
ECCT/23/03/05 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS… read more |
Principal Investigator(s) 1. Dr Primus Ochieng Site(s) in Kenya 1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)… read more |
View |
139. |
ECCT/23/03/06 | PDMC-II Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group,… read more |
Principal Investigator(s) 1. Simon Kariuki 2. Titus Kwambai Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
View |
140. |
ECCT/23/04/03 |
ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Prof Abraham Mosigisi Siika Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria… read more |
View |